History
A list of downloadable documents created during development.
Background information
-
-
Appendix A: Decision paper presented to the Institute's Guidance Executive
-
Appendix A: Decision paper presented to the Institute's Guidance Executive (PDF 105 KB)
-
-
Appendix A: provisional matrix of stakeholders
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 285 KB)
-
-
-
Summary of the responses from this consultation
-
Review decision - December 2008: table of comments (PDF 43 KB)
-
Review decision - December 2008: table of comments
-
Review decision - December 2008: table of comments (PDF 43 KB)
-
-
Provisional matrix of consultees and commentators (MSWord 67 KB)
Appeal outcome
-
-
Appeal outcome: Decision of the panel
-
Post-appeal final appraisal determination: Psoriasis - efalizumab and etanercept
Appeal details: Efalizumab and etanercept for psoriasis
Details of appeal announced
Final Appraisal Determination: Psoriasis - efalizumab and etanercept
-
Final Appraisal Determination: Psoriasis - efalizumab and etanercept information
-
Final Appraisal Determination: Efalizumab and etanercept for the treatment of adults with psoriasis
-
-
ACD tabulation of contents
-
-
Addendum following price change for infliximab
-
-
Addendum - additional analysis
-
-
Sensitivity analysis - Aug 05
-
Appeal announcement
Appraisal Consultation Document: Psoriasis - efalizumab and etanercept
Psoriasis - efalizumab and etanercept: assessment report
-
Psoriasis - efalizumab and etanercept: assessment report
-
Psoriasis - efalizumab and etanercept: assessment report (PDF 1.34 MB)
Economic addendum (1)
-
Economic addendum (1)
-
Economic addendum (2)
-
Economic addendum (2)
-
NICE technology appraisal: New treatments for moderate to severe psoriasis
Efalizumab and etanercept for the treatment of psoriasis - Final protocol
-
Efalizumab and etanercept for the treatment of psoriasis - Final protocol
-
Efalizumab and etanercept for the treatment of psoriasis - Final protocol (PDF 156 KB)
Efalizumab and etanercept for the treatment of moderate to severe psoriasis - Final Scope
-
Efalizumab and etanercept for the treatment of moderate to severe psoriasis - Final Scope
-
Archive: Efalizumab and etanercept for the treatment of psoriasis - Final Scope (PDF 81 KB)
Archive: Efalizumab and etanercept for the treatment of psoriasis - Final Scope
-
Archive: Efalizumab and etanercept for the treatment of psoriasis - Final Scope
-
Archive: Efalizumab and etanercept for the treatment of psoriasis - Final Scope (PDF 81 KB)